Endocytosis Inhibition in Humans to Improve Responses to ADCC-Mediating Antibodies | Zendy

Hui Yi Chew | Zendy; Priscila Oliveira de Lima | Zendy; Jazmina L. G. Cruz | Zendy; Blerida Banushi | Zendy; G O Echejoh | Zendy; Lingbo Hu | Zendy; Shan R. Joseph | Zendy; Benedict Lum | Zendy; James Rae | Zendy; Jake S. O’Donnell | Zendy; Lilia Merida de Long | Zendy; Satomi Okano | Zendy; Brigid King | Zendy; Rachael Barry | Zendy; Davide Moi | Zendy; Roberta Mazzieri | Zendy; Ranjeny Thomas | Zendy; Fernando SouzaFonsecaGuimaraes | Zendy; Matthew Foote | Zendy; Adam McCluskey | Zendy; Phillip J. Robinson | Zendy; Ian H. Frazer | Zendy; Nicholas A. Saunders | Zendy; Robert G. Parton | Zendy; Riccardo Dolcetti | Zendy; Katharine Cuff | Zendy; Jennifer Martin | Zendy; Benedict Panizza | Zendy; Euan Walpole | Zendy; James W. Wells | Zendy; Fiona Simpson | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Endocytosis Inhibition in Humans to Improve Responses to ADCC-Mediating Antibodies

Author(s) -

Hui Yi Chew,

Priscila Oliveira de Lima,

Jazmina L. G. Cruz,

Blerida Banushi,

G O Echejoh,

Lingbo Hu,

Shan R. Joseph,

Benedict Lum,

James Rae,

Jake S. O’Donnell,

Lilia Merida de Long,

Satomi Okano,

Brigid King,

Rachael Barry,

Davide Moi,

Roberta Mazzieri,

Ranjeny Thomas,

Fernando SouzaFonsecaGuimaraes,

Matthew Foote,

Adam McCluskey,

Phillip J. Robinson,

Ian H. Frazer,

Nicholas A. Saunders,

Robert G. Parton,

Riccardo Dolcetti,

Katharine Cuff,

Jennifer Martin,

Benedict Panizza,

Euan Walpole,

James W. Wells,

Fiona Simpson

Publication year - 2020

Publication title -

cell

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 26.304

H-Index - 776

eISSN - 1097-4172

pISSN - 0092-8674

DOI - 10.1016/j.cell.2020.02.019

Subject(s) - endocytosis , antibody dependent cell mediated cytotoxicity , biology , in vivo , monoclonal antibody , cetuximab , antibody , ex vivo , microbiology and biotechnology , cancer research , immunology , cell , biochemistry

A safe and controlled manipulation of endocytosis in vivo may have disruptive therapeutic potential. Here, we demonstrate that the anti-emetic/anti-psychotic prochlorperazine can be repurposed to reversibly inhibit the in vivo endocytosis of membrane proteins targeted by therapeutic monoclonal antibodies, as directly demonstrated by our human tumor ex vivo assay. Temporary endocytosis inhibition results in enhanced target availability and improved efficiency of natural killer cell-mediated antibody-dependent cellular cytotoxicity (ADCC), a mediator of clinical responses induced by IgG1 antibodies, demonstrated here for cetuximab, trastuzumab, and avelumab. Extensive analysis of downstream signaling pathways ruled out on-target toxicities. By overcoming the heterogeneity of drug target availability that frequently characterizes poorly responsive or resistant tumors, clinical application of reversible endocytosis inhibition may considerably improve the clinical benefit of ADCC-mediating therapeutic antibodies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research